SUNSHINE PHARMA (06887.HK): Compliance Adviser Changed, Yin Leung Capital (Asia Pacific) Appointed as New Adviser

NewTimeSpace News: On 31 August 2026, Sunshine Lake Pharma Co., Ltd. (stock code: 06887) announced that, by mutual agreement between the Company and Wa Sing Capital Limited, the compliance adviser agreement dated 29 May 2024 had been terminated on the same date. The termination was due to the resignation of a number of responsible officers of Wa Sing Capital, effective 31 August 2026, as a result of which Wa Sing Capital would no longer be qualified to provide compliance adviser services to the Company to an acceptable standard under Rule 3A.26 of the Listing Rules.

The Board announced that Yin Leung Capital (Asia Pacific) Limited has been appointed as the Company's new compliance adviser under Rule 3A.27 of the Listing Rules, with effect from 31 August 2026. Under Rule 3A.19 of the Listing Rules, its term of appointment will last until the date on which the Company publishes its financial results for the first full financial year commencing from the date of its listing (i.e. the financial year ended 31 December 2026) in compliance with Rule 13.46, or until the compliance adviser agreement with Yin Leung Capital is terminated in accordance with its terms, whichever is earlier.

According to the announcement, Yin Leung Capital is a licensed corporation under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities. Save as disclosed in the announcement, the Board and Wa Sing Capital each confirmed that, as of the date of the announcement, there are no other matters relating to the termination that need to be brought to the attention of the shareholders and the Stock Exchange.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.